Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis
Background Our study was designed to determine the safety, efficacy, and immunological effects of perioperative pembrolizumab in early-stage NSCLC.Methods This is a single-arm phase II study of perioperative pembrolizumab in patients with untreated, clinical stage IB to IIIA NSCLC. Patients received...
Saved in:
Main Authors: | Jeff Clarke, Xiaofei Wang, Thomas Stinchcombe, Scott J Antonia, Jeffrey Crawford, Neal Ready, Konstantin H Dragnev, Lin Gu, Cameron Wood, James M Isaacs, Liliana Lyniv, Kent Weinhold, Jacob M Kaufman, Eziafa I Oduah, Betty C Tong, Dennis Wigle |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2025-02-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/13/2/e010395.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
An Episode of Pseudothrombocytopenia during Pembrolizumab Therapy in NSCLC Patient
by: Kinga Krukowska, et al.
Published: (2020-01-01) -
Outcomes of Pembrolizumab plus chemotherapy for patients with metastatic non-squamous NSCLC: Real-world evidence
by: Irina Surovtsova, et al.
Published: (2025-12-01) -
Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50%
by: Yoshihito Kogure, MD, PhD, et al.
Published: (2025-03-01) -
Temporal Trends in the Utilization and Survival Outcomes of Lobar, Segmental, and Wedge Resection for Early-Stage NSCLC, 2004 to 2020
by: Eden Z. Deng, BS, et al.
Published: (2025-03-01) -
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry
by: Mieke Van Hemelrijck, et al.
Published: (2025-02-01)